Antituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study

Basit Öğe Kaydı
dc.authoridYemisen, Mucahit/0000-0002-6974-2585
dc.authoridYilmaz, Emel/0000-0002-3894-1231
dc.authoridSenbayrak, Seniha/0000-0002-4983-6613
dc.authoridozkutuk, nuri/0000-0002-2848-5914
dc.authoridCivljak, Rok/0000-0001-8766-7438
dc.authoridKayabas, Uner/0000-0002-5323-0796
dc.authoridErdem, Hakan/0000-0002-6265-5227
dc.contributor.authorSenbayrak, Seniha
dc.contributor.authorOzkutuk, Nuri
dc.contributor.authorErdem, Hakan
dc.contributor.authorJohansen, Isik Somuncu
dc.contributor.authorCivljak, Rok
dc.contributor.authorInal, Ayse Seza
dc.contributor.authorKayabas, Uner
dc.date.accessioned2025-01-27T20:24:49Z
dc.date.available2025-01-27T20:24:49Z
dc.date.issued2015
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground: Tuberculous meningitis (TBM) caused by Mycobacterium tuberculosis resistant to antituberculosis drugs is an increasingly common clinical problem. This study aimed to evaluate drug resistance profiles of TBM isolates in adult patients in nine European countries involving 32 centers to provide insight into the empiric treatment of TBM. Methods: Mycobacterium tuberculosis was cultured from the cerebrospinal fluid (CSF) of 142 patients and was tested for susceptibility to first-line antituberculosis drugs, streptomycin (SM), isoniazid (INH), rifampicin (RIF) and ethambutol (EMB). Results: Twenty of 142 isolates (14.1 %) were resistant to at least one antituberculosis drug, and five (3.5 %) were resistant to at least INH and RIF, [multidrug resistant (MDR)]. The resistance rate was 12, 4.9, 4.2 and 3.5 % for INH, SM, EMB and RIF, respectively. The monoresistance rate was 6.3, 1.4 and 0.7 % for INH, SM and EMB respectively. There was no monoresistance to RIF. The mortality rate was 23.8 % in fully susceptible cases while it was 33.3 % for those exhibiting monoresistance to INH, and 40 % in cases with MDR-TBM. In compared to patients without resistance to any firstline drug, the relative risk of death for INH-monoresistance and MDR-TBM was 1.60 (95 % CI, 0.38-6.82) and 2.14 (95 % CI, 0: 34-13: 42), respectively. Conclusion: INH-resistance and MDR rates seemed not to be worrisome in our study. However, considering their adverse effects on treatment, rapid detection of resistance to at least INH and RIF would be most beneficial for designing anti-TB therapy. Still, empiric TBM treatment should be started immediately without waiting the drug susceptibility testing.
dc.identifier.doi10.1186/s12941-015-0107-z
dc.identifier.issn1476-0711
dc.identifier.pmid26538030
dc.identifier.scopus2-s2.0-84946225326
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1186/s12941-015-0107-z
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22355
dc.identifier.volume14
dc.identifier.wosWOS:000364000400001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBiomed Central Ltd
dc.relation.ispartofAnnals of Clinical Microbiology and Antimicrobials
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectTuberculosis
dc.subjectMeningitis
dc.subjectResistance
dc.subjectMDR
dc.subjectIsoniazid
dc.titleAntituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu